Skip to Main Content

Advertisement

Skip Nav Destination

Issues

Highlights

Molecular Pathways

CCR Special Focus

Janet E. Dancey; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Kevin K. Dobbin; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Susan Groshen; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; J. Milburn Jessup; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Andrew H. Hruszkewycz; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Maria Koehler; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Ralph Parchment; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Mark J. Ratain; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Lalitha K. Shankar; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Walter M. Stadler; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Lawrence D. True; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Amy Gravell; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Michael R. Grever; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee

Review

Human Cancer Biology

Cancer Therapy: Preclinical

Imaging, Diagnosis, Prognosis

Cancer Therapy: Clinical

Susceptibility and Prevention

Letters to the Editor

or Create an Account

Close Modal
Close Modal